Ab&B Bio

Ab&B Bio is a South Korean biopharmaceutical company specializing in the development of multi-specific antibody therapeutics for cancer and inflammatory diseases. Founded in 2018 by Dr. Sang-Seok Koh, the company leverages its proprietary Ab&B-Body platform to create bispecific antibodies with enhanced stability, high productivity, and potent therapeutic efficacy. Its lead candidate, ABB-101, is a bispecific antibody targeting both Programmed cell death 1 ligand 1 (PD-L1) and Transforming growth factor beta (TGF-beta), aimed at treating advanced solid tumors that are resistant to existing checkpoint inhibitors. The company is currently advancing its pipeline through pre-clinical development while seeking strategic partnerships for clinical expansion.